c-RET

シグナル伝達経路

研究分野

  • 阻害剤の選択性比較
  • 溶解度
カタログ番号 製品カタログ 溶解度(25°C)
DMSO アルコール
S1178 Regorafenib (BAY 73-4506) <1 mg/mL 97 mg/mL <1 mg/mL
S1107 Danusertib (PHA-739358) <1 mg/mL 95 mg/mL <1 mg/mL
S2692 TG101209 <1 mg/mL 102 mg/mL <1 mg/mL
S8189 BAW2881 (NVP-BAW2881) <1 mg/mL 84 mg/mL 20 mg/mL
S8348 BMS-935177 <1 mg/mL 100 mg/mL 100 mg/mL
S5077 Regorafenib Monohydrate -1 mg/mL 100 mg/mL -1 mg/mL
S8696 2-D08 <1 mg/mL 54 mg/mL <1 mg/mL
S8518 AD80 <1 mg/mL 94 mg/mL 94 mg/mL
製品コード 製品説明 文献中の使用例 お客様のフィードバック
S1178

Regorafenib (BAY 73-4506)

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

S1107

Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.

S2692

TG101209

TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM in cell-free assays, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations.

S8189

BAW2881 (NVP-BAW2881)

BAW2881 (NVP-BAW2881) is a novel vascular endothelial growth factor (VEGF) receptor tyrosine-kinase inhibitor that potently inhibits VEGFR1-3 at 1.0-4.3 nanomolar (nM) concentrations and inhibits PDGFRβ, c-Kit, and RET at 45-72 nM concentrations.

S8348

BMS-935177

S5077

Regorafenib Monohydrate

S8696

2-D08

S8518

AD80

AD80, a multikinase inhibitor, shows strong activity against human RET, BRAF, S6K, and SRC but were much less active than either AD57 or AD58 against mTOR. The IC50 value for RET is 4 nM.